|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 555 11th STREET, NW |
Address2 | Suite #300 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Ilhaam Illy Jaffer |
Date | 1/6/2022 4:42:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding of the World Health Organization and for cervical cancer screening & treatment and HPV vaccination; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE).
HR 133, Consolidated Appropriations Act, 2021
HR 8337, Making continuing appropriations for fiscal year 2021, and for other purposes
HR 925, the HEROES Act
HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
HR 748, Coronavirus Aid, Relief, and Economic Security Act
HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act
H.R.7610, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021
S 178, Legislative vehicle for the Protect Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), U.S. Agency for International Development (USAID), Energy - Dept of, Defense - Dept of (DOD), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:
HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act
HR 1948, Lymphedema Treatment Act;
HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills;
HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Senate introduction (no bill number just yet);
Issues related to Medicaid Non-Emergency Medical Transportation; and
Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement.
HR 2477, Beneficiary Enrollment Notification and Eligibility Simplification Act (BENES)
Regulatory issues related to Medicaid and value-based payment
HR 7663, Protecting Access to Post COVID 19 Telehealth Act of 2020
The Access to Genetic Counselor Services Act of 2019, HR 3235
Advocacy w. CMS related to state Medicaid 1115 waiver approvals
Multi-Cancer Early Detection Screening Coverage Act of 2020, HR 8845
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:
Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation;
Issues relating to FDA regulation of electronic cigarettes and cigars;
H.R, 7286 and S 4524, the Quit Because of COVID-19 Act:
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office, Federal Trade Commission (FTC), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations.
Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act.
Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending), S. 178 (legislative vehicle for the Protect Act), and HR 925, The Heroes Act.
Medical expense deduction - lowering the percentage to 7.5%
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Federal Reserve System, Small Business Administration (SBA), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Keysha |
Brooks-Coley |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including:
HR 6514, Worker Health Coverage Protection Act
HR 1425, Patient Protection and Affordable Care Enhancement Act
Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination
HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act
Issues related to the Senate HELP Committee initiative on preparing for future pandemics.
Regulatory issues related to telehealth
Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019;
Issues relating to curbing health care costs;
H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act;
Anti-cancer medication cost-sharing parity respecting H.R. 1409;
A national family caregiving strategy respecting S. 1719 and H.R. 1028;
Access to medicines respecting FDA implementation of right to try law;
Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020;
H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for;
H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials;
Additional issues related to reducing health disparities in cancer clinical trials;
Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus;
H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act;
H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day
H.R. 1730 and S. 741, the Cancer Drug Parity Act;
Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ;
H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019
S. 2497, the Dependent Income Exclusion Act;
Issues related to HHS regulation of prescription drug prices and costs;
H.R. 4439, Creating Hope Reauthorization Act;
H.R. 1730 and S. 741, the Cancer Drug Parity Act;
H.R. 6556, the Gabriella Miller Kids First Research Act 2.0;
H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act;
H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus;
Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care;
Issues related to improving data collection during the COVID-19 pandemic; and
H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19.
S 4557, COVID Enrollment Response Act (Sen. Baldwin)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), White House Office, State - Dept of (DOS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law.
Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Keysha |
Brooks-Coley |
|
|
|
Stephanie |
Krenrich |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |